FDA Clears Bonhawa High-Flow Oxygen Therapy System
The FDA granted 510(k) clearance to the Bonhawa high-flow oxygen therapy system, designed to enhance the treatment of patients with respiratory insufficiency.
The FDA granted 510(k) clearance to the Bonhawa high-flow oxygen therapy system, designed to enhance the treatment of patients with respiratory insufficiency.
According to new research published in Thorax, the use of noninvasive breathing support to treat patients with moderate to severe COVID-19 in hospitals isn’t linked to a heightened risk of transmitting infection to others.
Universal administration of high-flow oxygen therapy for all acute coronary syndrome patients may not be beneficial, except for hypoxic ST-segment elevation MI (STEMI) patients.
The use of high-flow oxygen therapy delivered via high-flow nasal cannula is becoming more prevalent in hospitals as clinicians search for viable and effective alternatives to more invasive, costlier treatments.
Read MoreAlthough design plays an important role in selection of oxygen delivery devices, clinical assessment and performance ultimately determine which device should be selected.
Read MoreBy emphasizing mobility and therapeutic value, manufacturers of supplemental oxygen delivery systems continue to provide patients with more options and more freedom to integrate the therapy into their lives.
Read MoreA focus on outcomes is driving RTs to expand their delivery of oxygen therapy (and other care) out of the hospital and into the home.
Read MoreBased on clinical evidence, the utilization of high-flow oxygen (HFO) therapy via high-flow nasal cannula (HFNC) can improve oxygenation, decrease the patient’s work of breathing, and serve as an alternative to more invasive forms of treatment.
Read More